Phase II trial of MGN 1703 in patients with advanced non-small cell lung cancer who have responded to first-line chemotherapy.
Phase of Trial: Phase II
Latest Information Update: 10 Oct 2013
At a glance
- Drugs Lefitolimod (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms IMPACT-2
- Sponsors Mologen
- 10 Oct 2013 Status changed from planning to discontinued. A trial in small cell lung cancer will replace the trial application submitted for the non-small cell lung cancer trial, according to a Mologen media release.
- 15 Mar 2012 The trial protocol has been amended, according to a Mologen AG media release.
- 13 Jun 2011 New trial record